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Parkinson disease (PD), a chronic neuro-
degenerative disease, is characterized by pro-
gressive and selective degeneration of
dopaminergic (DA) neurons in the substantia
nigra (Leenders and Oertel 2001). Although
the etiology of PD is still unknown, many
environmental toxins and other environmen-
tal pathomechanisms (pharmacologic, infec-
tious, and traumatic) have been implicated.
Arai et al. (2006) suggested that infection and
inﬂammatory reaction potentially contribute
to the pathogenesis of PD.
Inflammatory mediators and cellular
processes once thought to be restricted to the
peripheral immune system are now known to
be vital in the progression of PD (Block et al.
2007; Hirsch et al. 1998; McGeer et al. 1988).
Microglia, the resident immune cells and major
phagocytes in the brain, have recently gained
prominence as a key mediator in the inﬂamma-
tory process of PD. Massive microglial activa-
tion in the substantia nigra and striatum has
been observed in brains from patients with PD
(McGeer et al. 1988). Activated microglia exert
cytotoxic effects by releasing inflammatory
mediators, such as reactive oxygen species
(ROS) and proinflammatory factors (Block
et al. 2007). Large amounts of these substances
are toxic to adjacent neurons, and the contin-
ued production of these mediators by activated
microglial cells can lead to chronic degenera-
tion of DA neurons, as seen in progressive PD.
Activation of microglia can be regulated by
both endogenous immune modulators and
exogenous substances (Block et al. 2007).
Previously we identified several endogenous
neuropeptides, such as substance P, dynorphin,
and pituitary adenylate cyclase-activating
polypeptide, that can modulate microglial
activity and DA neuron survival in sub-
picomolar to femtomolar concentrations
(Block et al. 2006; Yang et al. 2006) in rodent
midbrain neuron/glia (N/G) cultures. We per-
formed pharmacophore perception to search
for other naturally occuring peptides that are
chemically related to these neuropeptides to
determine if they exhibit similar neuro-
protective or neurotoxic functions. We found
that formyl-methionyl-leucyl-phenylalanine
(fMLP), a bacterial-derived chemoattractant,
has high chemical similarity with substance P.
Several chemical features shared between
fMLP and substance P, as deduced by the
Catalyst/HipHop program (Accelrys, Inc.,
San Diego, CA), include a hydrogen bond
acceptor, a hydrogen bond donor, a positively
ionizable region, and a hydrophobic group
(Figure 1). Based on this result, fMLP might
share similar binding properties to microglia
as substance P and hence trigger similar bio-
logical pathways. This discovery prompted us
to speculate that fMLP might be another pep-
tide that can affect DA neuron toxicity in a
microglia-dependent manner.
fMLP, an N-formylated peptide, is a potent
chemoattractant molecule released from both
bacteria and damaged mitochondria, and it
plays an important role in host defense against
microbial infection or tissue injury by recruit-
ing phagocytes to the site of inflammation.
fMLP may exist in the brain in some infectious
diseases of the central nervous system (CNS),
such as meningitis. Circulating fMLP released
from bacteria may also enter the brain through
areas with a less tight blood–brain barrier, such
as the circumventricular organs (Duvernoy and
Risold 2007). Two functional formyl peptide
receptors (FPRs), designated FPR and
FPRL1R, bind fMLP with high (FPR, in the
low nanomolar or picomolar range) and low
(FPRL1R, in the micromolar range) afﬁnity,
respectively (Hartt et al. 1999). Expression of
FPR has been observed in rodent microglia
(Lorton et al. 2000). However, microglial cells
lack the capacity to migrate in response to
fMLP (Yao et al. 1990), suggesting that the
expression of FPRs on microglia is either absent
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BACKGROUND: Parkinson disease (PD), a chronic neurodegenerative disease, has been proposed to
be a multifactorial disorder resulting from a combination of environmental mechanisms (chemical,
infectious, and traumatic), aging, and genetic deficits. Microglial activation is important in the
pathogenesis of PD.
OBJECTIVES: We investigated dopaminergic (DA) neurotoxicity and the underlying mechanisms of
formyl-methionyl-leucyl-phenylalanine (fMLP), a bacteria-derived peptide, in relation to PD.
METHODS: We measured DA neurotoxicity using a DA uptake assay and immunocytochemical
staining (ICC) in primary mesencephalic cultures from rodents. Microglial activation was observed
via ICC, ﬂow cytometry, and superoxide measurement.
RESULTS: fMLP can cause selective DA neuronal loss at concentrations as low as 10–13 M. Further,
fMLP (10–13 M) led to a signiﬁcant reduction in DA uptake capacity in neuron/glia (N/G) cul-
tures, but not in microglia-depleted cultures, indicating an indispensable role of microglia in fMLP-
induced neurotoxicity. Using ICC of a speciﬁc microglial marker, OX42, we observed morphologic
changes in activated microglia after fMLP treatment. Microglial activation after fMLP treatment
was conﬁrmed by ﬂow cytometry analysis of major histocompatibility antigen class II expression on
a microglia HAPI cell line. Mechanistic studies revealed that fMLP (10–13 M)-induced increase in
the production of extracellular superoxide from microglia is critical in mediating fMLP-elicited
neurotoxicity. Pharmacologic inhibition of NADPH oxidase (PHOX) with diphenylene-iodonium
or apocynin abolished the DA neurotoxicity of fMLP. N/G cultures from PHOX-deficient
(gp91PHOX–/–) mice were also insensitive to fMLP-induced DA neurotoxicity.
CONCLUSION: fMLP (10–13 M) induces DA neurotoxicity through activation of microglial PHOX
and subsequent production of superoxide, suggesting a role of fMLP in the central nervous system
inﬂammatory process.
KEY WORDS: fMLP, inflammation, microglia, NADPH oxidase, neurotoxicity. Environ Health
Perspect 116:593–598 (2008). doi:10.1289/ehp.11031 available via http://dx.doi.org/ [Online
30 January 2008]
Researchor too low to function. Therefore, in spite of all
the studies on fMLP in phagocytes during the
peripheral inflammatory response, little is
known about the function of fMLP in the CNS
inﬂammatory process.
In the present study, we investigated the
function of fMLP in neurodegeneration,
using the well-established primary rat and
mouse midbrain culture model of PD. Our
results showed that a subpicomolar concen-
tration of fMLP (10–13 M) induces oxidative
stress through activation of NADPH oxidase
(also called phagocyte oxidase; PHOX) in
microglia, resulting in selective DA neuro-
toxicity. Here, for the first time, we provide
evidence for an effect of fMLP in the CNS
inflammatory process and propose a new
potential mediator between infectious and
neurodegenerative diseases in the brain.
Materials and Methods
Reagents. We purchased fMLP, L-leucine
methyl ester hydrobrimide (LME), 3,3´-
diaminobenzidine, and urea-hydrogen peroxide
tablets from Sigma Chemical Co. (St. Louis,
MO). Lipopolysaccharide (LPS; strain
O111:B4) was purchased from Calbiochem
(San Diego, CA). Cell culture ingredients were
obtained from Invitrogen (Carlsbad, CA). We
purchased [3H]DA (30 Ci/mmol) and [3H]γ-
aminobutyric acid (GABA; 90 Ci/mmol) from
PerkinElmer Life Sciences (Boston, MA). We
obtained monoclonal antibodies against the
CR3 complement receptor (OX-42) from
Chemicon (Temecula, CA), and polyclonal
antibody against Iba-1 from Wako Chemicals
USA, Inc. (Richmond, VA). Vectastain avidin-
biotinylated enzyme complex, biotinylated
horse anti-mouse antibody, and goat anti-rabbit
secondary antibody were purchased from
Vector Laboratories (Burlingame, CA).
Animals. We obtained wild-type C57BL/6J
(gp91phox+/+) and NADPH oxidase (PHOX)-
deﬁcient (gp91phox–/–) mice from the Jackson
Laboratory (Bar Harbor, ME). We bred the
mice to obtain timed pregnancy with accuracy
of 0.5 day. Timed-pregnant Fisher F344 rats
were obtained from Charles River Laboratories
(Raleigh, NC). Animals were treated humanely
and with regard for alleviating suffering.
Housing and breeding of animals were done in
accordance with National Institutes of Health
guidelines (Office of Laboratory Animal
Welfare 2002). All animals were housed in a
speciﬁc pathogen-free facility in conditions of a
constant temperature and relative humidity.
Animals had ad libitum access to a standard
laboratory chow and were kept on a 12-hr
light/dark cycle.
Mesencephalic N/G cultures. We prepared
N/G cultures from the ventral mesencephalic
tissues of embryonic day 13–14 rats or day
12–13 mice as described previously (Liu et al.
2000). Brieﬂy, dissociated cells were seeded at
5 × 105/well in a 24-well plate coated with
poly-D-lysine. Cells were incubated in a
humidiﬁed atmosphere at 37°C, with 5% CO2
and 95% air, and in minimal essential medium
containing 10% fetal bovine serum, 10% horse
serum, 1 g/L glucose, 2 mM L-glutamine,
1 mM sodium pyruvate, 100 µM nonessential
amino acids, 50 U/mL penicillin, and
50 µg/mL streptomycin. Cells were ready for
treatment 7 days after initial seeding. We esti-
mated the composition of major cell types in
the culture by visually counting immuno-
stained cells with antibodies against cell
type–specific markers: about 40–41% neu-
rons, 11–12% microglia, 48% astrocytes, and
1% tyrosine hydroxylase-immunoreactive
(TH-IR) neurons.
Mesencephalic microglia-depleted cultures.
Mesencephalic N/G cultures were prepared
as described above. Two days after the initial
seeding of the cells, 1.5 mM LME (ﬁnal con-
centration) was added to the cultures and was
kept in the cultures for 72 hr to deplete
microglia. Seven-day-old cultures, which
contain < 0.1% microglia, were used for
treatment.
[3H]DA or [3H]GABA uptake assay. We
inclubated the cultures for 20 min at 37°C with
1µ M  [ 3H]DA or 5 µM [3H]GABA in Krebs-
Ringer buffer (16 mM Na2HPO4, 119 mM
NaCl, 4.7 mM KCl, 1.2 mM MgSO4,
1.3 mM EDTA, pH 7.4). We measured non-
speciﬁc DA uptake in the presence of 10 µM
mazindol. Nonspeciﬁc uptake was blocked for
GABA with 10 µM NO–711 and 1 mM β-ala-
nine. After incubation, the cells were washed
with ice-cold Krebs-Ringer buffer and lysed
with 1 N NaOH. We mixed cell lysates with
15 mL scintillation fluid. Radioactivity was
measured with a Beckman Tri-carb 2900 TR
liquid scintillation counter (Beckman Coulter,
Fullerton, CA). We calculated by subtracting
the nonspeciﬁc counts from that of the wells
without the uptake inhibitors.
Superoxide assay. We determined the extra-
cellular superoxide production by measuring
the superoxide dismutase (SOD)-inhibitable
reduction of the water-soluble tetrazolium salt
WST-1, using modifications of a previously
described method (Gao et al. 2002). Cultures
were washed twice and left in 100 µL Hanks’
balanced salt solution (HBSS). We added
50 µL HBSS, LPS, or fMLP, then 50 µL
WST-1 (1 mM) in HBSS, with or without
SOD (600 U/mL). We read the absorbance at
450 nm immediately with a Spectra Max Plus
microtiter plate spectrophotometer (Molecular
Devices, Sunnyvale, CA).
Flow cytometry. Highly aggressively prolif-
erating immortalized (HAPI) microglial cells,
a microglial-like rat cell line, were seeded in
6-well plates (9.6 cm2) at 5 × 105 cells/well
and grown in Dulbecco’s minimal essential
medium with 10% fetal bovine serum to 85%
confluence. Cells were stimulated with LPS
(10 ng/mL) or fMLP (10–13 M) for 48 hr, dis-
lodged in HBSS, pelleted (1,000 × g for 5 min
at 4°C), and resuspended in ice-cold blocking
solution (HBSS containing 1% BSA) for
20 min. We washed cells and stained them for
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Figure 1. Pharmacophore analysis between fMLP and substance P. Similar chemical features shared by
these two peptides are illustrated by three-dimensional relationships with the highest fit values. fMLP
resembles the amino acid sequence (Phe-Phe-Gly-Leu-Met) of the C-terminus of substance P. Hydrogen
bond acceptor (HBA), green; negative ionizable, dark blue; hydrophobic, light blue.30 min on ice with a 1:200 dilution of phyco-
erythrin-conjugated anti-rat OX6 (BD
Pharmingen, San Diego, CA). We ran iso-
type-matched controls in parallel. Cells were
then washed three times and fixed. Analysis
was performed on a FACScan ﬂow cytometer
using FACSDiva software (BD Biosciences,
San Jose, CA).
Immunocytochemistry (ICC). We stained
DA neurons with the antibody against tyro-
sine hydroxylase. Microglia were stained
with the antibody raised against OX42 or
Iba-1 antigen for rat and mouse primary cul-
tures, respectively. In brief, 3.7% formalde-
hyde-fixed cultures were treated with 1%
hydrogen peroxide (10 min), followed by
sequential incubation with blocking solution
(20 min), primary antibody (overnight,
4°C), biotinylated secondary antibody
(1 hr), and Vectastain ABC reagents (1 hr).
After washing, the bound complex was visu-
alized by incubating cells with 3,3´-diamino-
benzidine and urea-hydrogen peroxide
tablets dissolved in water. We terminated
color development by removing the reagents
and washing the cultures with PBS. Images
were recorded with an inverted microscope
(Nikon, Tokyo, Japan) connected to a charge-
coupled device camera (DAGE-MTI,
Michigan City, IN) operated with MetaMorph
software (Universal Imaging Corporation,
Downingtown, PA). Nine representative areas
per well of a 24-well plate were counted under
the microscope at 100× magniﬁcation.
Pharmacophore analysis. We used the
Catalyst, version 4.9.1 software (Accelrys) for
conformational and pharmacophore analysis.
All molecules were built within the Catalyst
modeling software, and peptides were con-
structed as linear chains. The maximum num-
ber of conformers generated for each molecule
was 250. We removed conformers with rela-
tive energy > 20 kcal/mol, and we used the
best (most rigorous and most time-consum-
ing) conformer generation method. The fol-
lowing chemical features were included in the
development of the pharmacophore model:
hydrogen bond acceptor, hydrogen bond
donor, hydrophobic group, negative charge or
negatively ionizable region, positively ioniz-
able region, aromatic ring, and hydrophobic
aromatic region.
Statistical analysis. The data are expressed
as mean ± SD. We assessed statistical signiﬁ-
cance between two groups with an analysis of
variance (ANOVA), followed by Student’s
t-test. Statistical signiﬁcance between multiple
groups was performed using a one-way
ANOVA. A value of p < 0.05 was considered
statistically signiﬁcant.
Results
MLP induces selective DA neurotoxicity. We
used the well-established primary mesencephalic
N/G culture system as an in vitro model to
investigate the possible role of fMLP in CNS
neurodegenerative diseases. Cultures were
treated with fMLP (10–7, 10–9, 10–11, 10–13,
or 10–15 M) for 8 days. The degeneration of
DA neurons was determined by [3H]DA
uptake assay and cell count. As shown in
Figure 2A, fMLP at 10–7 to 10–13 M signiﬁ-
cantly reduced the capacity of cultures to take
up DA versus vehicle control. LPS, which is
well known as an endotoxin and inﬂammatory
agent, was used as a positive control to induce
selective damage to DA neurons through acti-
vation of microglia. Although the regulation
of many important biological functions of
neutrophils requires a relatively high concen-
tration (> 10–7 M) of fMLP (Balazovich et al.
1996; Elbim et al. 1993), it is rare for
microglia to be exposed to such high concen-
trations due to the diffusion in the peripheral
blood system and the difﬁculty of passing the
blood–brain barrier. Therefore, although DA
neurotoxicity was observed at higher concen-
trations of fMLP treatment, we focused on the
effect of fMLP at 10–13 M, which might be
close to the physically relevant concentration
of fMLP in CNS. We used [3H]GABA uptake
as an index for the selectivity of fMLP-
induced toxicity. Figure 2B indicates that
fMLP (10–13 M) failed to show any effect on
[3H]GABA uptake capacity, indicating that
fMLP is selectively toxic to DA neurons.
Using ICC staining of TH, we observed mor-
phologic changes in DA neurons after fMLP
treatment (Figure 2D). The number of
TH-IR neurons was counted as another index
of neurotoxicity (Figure 2C). Consistent with
our uptake results, fMLP (10–13 M) signifi-
cantly reduced the number of TH-IR neurons.
Microglia are indispensable to sub-
picomolar fMLP-induced DA neurotoxicity.
To determine the role of microglia in fMLP-
induced neurotoxicity, we treated rat primary
mesencephalic N/G cultures with LME
(1.5 mM) to deplete microglia. Seven days
after initial seeding, cultures were treated with
fMLP (10–13 M). Eight days after the treat-
ment, fMLP (10–13 M) resulted in signiﬁcant
reduction of DA uptake in N/G cultures, but
it failed to reduce DA uptake in microglia-
depleted cultures (Figure 3A).
Morphologic changes in microglia were
visualized 24 hr after treatment by ICC stain-
ing of OX-42, a specific microglial marker
recognizing the CR3 receptor. We used LPS-
treated cultures as a positive control to show
the morphologic change of microglial activa-
tion. As shown in Figure 3B, N/G cultures
treated with fMLP (10–13 M) displayed
intensified OX-42 immunoreactivity com-
pared with vehicle control. OX-42-positive
microglia cells demonstrated characteristics
of activation, including increased cell size and
amoeboid-like shape.
We also used HAPI rat microglia cells to
determine the effect of 10–13 M fMLP on the
expression of immune markers of microglia.
We measured expression of major histo-
compatibility antigen class II (MHCII, OX-6)
by flow cytometry analysis 24 hr after treat-
ment (Figure 3C). MHC-II was chosen as a
marker for microglia activation because
MHCII-positive activated microglia in the
substantia nigra may be involved in progressive
Neurotoxicity of fMLP via microglial activation
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Figure 2. Effect of fMLP on rat primary mesencephalic N/G cultures 8 days after treatment with vehicle
(control), LPS (5 ng/mL) as a positive control, or different concentrations of fMLP. (A) DA neurotoxicity
measured using the [3H]DA uptake assay; values are mean ± SD from four independent experiments in trip-
licate. (B) GABA neurotoxicity measured using the [3H]GABA uptake assay; values are mean ± SD from
three independent experiments in triplicate. (C) Effect of fMLP (10–13 M) on dopaminergic neurons observed
by immunocytochemistry staining with antibody against TH; DA neurotoxicity was measured by counting
TH-IR neurons 8 days after treatment. Values are mean ± SD from three independent experiments in tripli-
cate. (D) Representative images shown from three separate experiments for TH-IR neurons in a control cul-
ture and in cultures treated with LPS and fMLP. Bar = 50 µm.
*p < 0.05 compared with control.
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MHCII expression on untreated HAPI cells is
very low; fMLP (10–13 M) treatment signiﬁ-
cantly increased the expression of MHCII
compared with control cultures. Taken
together, the preceding data demonstrate that
microglia were activated after 10–13 M fMLP
treatment and that activated microglia play an
indispensable role in subpicomolar fMLP-
induced DA neurotoxicity.
Subpicomolar fMLP induces production
of superoxide from microglia. Oxidative stress
has been frequently observed in several neuro-
logic disorders, including PD (Jenner 2003).
Micromolar concentrations of fMLP have
been shown to stimulate the production of
superoxide anion in neutrophils (Dewald and
Baggiolini 1985; Sakamoto et al. 2006). In
the present study, we investigated whether
fMLP can induce the production of super-
oxide in microglia. N/G cultures were seeded
in 96-well plates and then treated with vehi-
cle, LPS (10 ng/mL), or fMLP (10–13 M).
The generation of extracellular superoxide
was measured as SOD-inhibitable reduction
of WST-1. fMLP (10–13 M) significantly
stimulated the release of extracellular superoxide
(Figure 3D) compared with vehicle control.
Microglial PHOX is a key contributor
mediating neurotoxicity of subpicomolar fMLP.
NADPH oxidase (PHOX) is the major enzyme
involved in the production of extracellular
superoxide in phagocytes (Babior 1999). To
determine whether microglial PHOX plays an
important role in fMLP-induced neurotoxicity,
we pharmacologically inhibited microglial
PHOX in primary rat mesencephalic N/G cul-
tures using diphenylene-iodonium (DPI) or
apocynin. We used 10–9 M DPI because DPI
at this concentration is effective at inhibiting
PHOX activity without any observable neuro-
toxicity (Qin et al. 2002). Cultures were pre-
treated with or without DPI (10–9 M) or
apocynin (0.2 mM) for 30 min before fMLP
(10–13 M) treatment. We determined DA
neurodegeneration 8 days after treatment by
[3H]DA uptake assay. Both DPI and apocynin
significantly attenuated fMLP (10–13 M)-
induced neurotoxicity, with 21% and 19%
increases in DA uptake capacity, respectively,
compared with fMLP (10–13 M) alone
(Figure 4A). DPI or apocynin alone had no
effect on DA uptake capacity.
To further study the role of PHOX in
mediating fMLP-induced neurotoxicity, we
used mutant mice deﬁcient in gp91, the cata-
lytic subunit of this superoxide-producing
enzyme. N/G cultures from wild-type
(gp91PHOX+/+) mice and mutant (gp91PHOX–/–)
mice were treated with vehicle or fMLP
(10–13 M). Eight days later, we assessed DA
neurotoxicity by [3H]DA uptake assay
(Figure 4B). fMLP markedly decreased DA
uptake capacity by 32% compared with vehi-
cle in wild-type (gp91PHOX+/+) mice cultures,
but it failed to show any DA neurotoxicity
in mutant (gp91PHOX–/–) mice cultures.
Morphologic analysis of microglial activation
was performed by ICC staining of Iba-1
(Figure 4C), a calcium-binding protein speciﬁc
to microglia. As early as 24 hr after fMLP
(10–13 M) treatment, activated microglia with
irregular shape, enlarged cell size, and enhanced
Iba-1 immunoactivity were observed in wild-
type mice cultures but not in mutant mice cul-
tures. These data confirm the critical role of
microglial PHOX in DA neurotoxicity induced
by subpicomolar fMLP.
Discussion
Using primary rat mesencephalic N/G and
microglia-depleted cultures, we showed that
fMLP causes selective DA neurodegeneration
at concentrations of 10–7 M to 10–13 M and
that microglia are actively involved in the
fMLP (10–13M)-induced DA neuronal loss.
An increase in the release of superoxide anion
generated by microglial PHOX plays a vital
role in the neurotoxicity of subpicomolar con-
centrations of fMLP, as demonstrated by the
reduction in fMLP-induced DA toxicity fol-
lowing pharmacologic inhibition or in geneti-
cally engineered knockout mice devoid of
PHOX activity.
Traditionally, fMLP is recognized as a
strong chemoattractant and activator of
phagocytic cells in peripheral blood, leading
to release of oxygen-derived free radicals,
which results in removal of invading micro-
organisms, thereby playing a key role in the
immune response to infection and inﬂamma-
tion (Panaro and Mitolo 1999). fMLP can
induce cell adherence and degranulation in
peripheral phagocytic cells, such as neutro-
phils, in the blood (Videm and Strand 2004).
fMLP triggers the FPRs on neutrophils to
activate PHOX, generating bactericidal super-
oxide anion and proinflammatory cytokines
(Dewald and Baggiolini 1985; Sakamoto
et al. 2006). However, studies on the effect of
fMLP on microglia have been limited due to
the fact that microglial cells lack the capacity
to migrate in response to fMLP (Yao et al.
1990). Interestingly, our pharmacophore
analysis illustrates that fMLP and substance P
share common chemical features, and previ-
ous studies by our group indicated that sub-
picomolar concentrations of substance P are
selectively toxic to DA neurons through
microglia-generated oxidative stress responses
(Block et al. 2006). Thus, we hypothesized
that fMLP, although lacking activity as a
chemoattractant for microglia, may activate
microglia and cause inﬂammation-related DA
toxicity similarly to substance P. The results
given here demonstrate that fMLP (10–13 M)
is selectively toxic to DA neurons after 8 days
of treatment in primary rat mesencephalic
N/G cultures (Figure 2). We conclude that
the neurotoxicity observed in these cultures is
Gao et al.
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Figure 3. Effects of subpicomolar fMLP on microglial activation in primary rat N/G cultures (LME–) or
microglia-depleted cultures (LME+) treated with vehicle, LPS (5 ng/mL; positive control for microglia activa-
tion), or fMLP (10–13 M). (A) DA neurotoxicity measured using the [3H]DA uptake assay 8 days after treat-
ment; values are mean ± SD from three independent experiments in triplicate. (B) Activation of microglia
visualized by immunocytochemical staining using OX-42 antibody 24 hr after LPS (5 ng/mL) or fMLP (10–13 M)
treatment in rat mecencephalic N/G cultures. Representative images are shown from three separate exper-
iments; bar = 50 µm. (C, D) Expression of MHCII (OX-6) in the HAPI rat microglial line treated with LPS
(10 ng/mL) or fMLP (10–13 M) measured by ﬂow cytometry (C) and by ﬂuorescence compared with isotype-
matched controls (D); values are mean ± SD from three independent experiments. (E) Production of extra-
cellular superoxide in N/G cultures from rats treated with vehicle, LPS (10 ng/mL), or fMLP (10–13 M) and
measured by the SOD-inhibitable reduction of WST-1; values are mean ± SD from ﬁve independent experi-
ments in triplicate.
*p < 0.05 compared with control cultures.
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fMLPmediated by microglial cells based on the fol-
lowing observations: a) Microglia were found
to be activated 24 hr after fMLP (10–13 M)
treatment, changing from resting ramified
microglia into activated amoeboid ones
(Figure 3B); b) the membrane expression of
MHCII (OX-6), a marker of activated
microglia, increased significantly after fMLP
(10–13 M) treatment (Figure 3C); and
c) fMLP (10–13 M) failed to induce degenera-
tion of DA neurons in microglia-depleted cul-
tures (Figure 3A), suggesting an indispensable
role of microglia in subpicomolar fMLP-
induced DA neurodegeneration.
Activated microglia can produce and release
a large number of proinflammatory factors,
including free radicals such as superoxide
(Roepstorff et al. 2007) and nitric oxide (Liu
et al. 2002), as well as proinflammatory
cytokines, such as interleukin (IL)-1β and
tumor necrosis factor (TNF)-α (Mogi et al.
1996; Nagatsu and Sawada 2007). Although
these immunotoxic factors are necessary for
normal function, the microglial response must
be tightly regulated to avoid overactivation and
disastrous neurotoxic consequences. Over-
production of ROS from microglia may be
toxic to DA neurons through two major path-
ways: a) Production of extracellular superoxide
is directly toxic to DA neurons; and b) thegen-
erated superoxide can subsequently be dismu-
tated to cell-permeable hydrogen peroxide
(Paravicini et al. 2004), resulting in an increase
in intracellular ROS. Intracellular ROS in
microglia is a critical component of pro-
inﬂammatory signaling and ampliﬁes the pro-
duction of neurotoxic proinﬂammatory factors,
such as nitric oxide and TNF-α (Block et al.
2007). In the present study, 10–13 M fMLP sig-
niﬁcantly stimulated microglia to release extra-
cellular superoxide compared with vehicle
(Figure 3D). The microglial production of
extracellular superoxide might be responsible
for the subpicomolar fMLP-induced neuro-
toxicity. Intracellular ROS levels were also
measured in enriched microglia cultures after
stimulation with fMLP (10–13 M), showing a
slight increase in ﬂuorescent signal compared
with the vehicle cultures (data not shown).
Therefore, production of intracellular ROS and
its downstream reactions may also be involved
in fMLP-induced neurotoxicity, but to a lesser
extent. The production of nitric oxide and
TNF-α were below the detection limits of the
assays after fMLP (10–13 M) treatment (data
not shown). However, we cannot rule out the
possibility of their contribution to fMLP-
induced DA neurotoxicity. Low quantities of
nitric oxide, for instance, may react with super-
oxide free radicals to form peroxynitrite, which
is highly neurotoxic (Beckman et al. 1993).
The exact mechanisms by which fMLP exerts
its neurotoxic effect on DA neurons through
microglial activation remains to be determined.
Data from this study suggest that PHOX is
critical for subpicomolar fMLP regulation of
microglial activation and vital in fMLP-
induced DA neurotoxicity. Pharmacologic
inhibition of PHOX or genetic knockout of
the gp91 subunit of PHOX completely abol-
ished fMLP-induced DA neurotoxicity
(Figure 4). However, whether fMLP (10–13 M)
mediates glial cell activation by directly inter-
acting with PHOX or indirectly through the
FPRs is not clear. There is evidence that fMLP
may activate the p38 mitogen-activated protein
kinase or phosphatidylinositol 3-kinase signal
transduction pathways via the activation of
FPRs and lead to the activation of neutrophil
PHOX (Fu et al. 2004). Accumulating evi-
dence indicates that the expression of high-
affinity FPR in microglial cells is subject to
up-regulation by both pathogen- and host-
derived molecules associated with inﬂamma-
tory responses such as LPS (Cui et al. 2002a),
and the proinflammatory cytokines TNF-α
(Cui et al. 2002b) and interferon-γ (Chen et al.
2007). However, high-afﬁnity FPR binds and
is activated by fMLP in picomole to low nano-
mole concentrations (Le et al. 2000). There are
no reports of FPRs being activated by sub-
picomolar concentrations of fMLP. In fact,
many femtomolar-acting compounds tested in
our laboratory, such as substance P, dynorphin
(Block et al. 2006), naloxone (Qin et al. 2005),
and dextromethorphan (Liu et al. 2001) are
independent of traditional receptor-mediated
mechanisms. PHOX seems to be a common
pathway for these femtomolar-acting com-
pounds. Ongoing research in our laboratory is
trying to elucidate the action site of sub-
picomolar fMLP. Given the importance of
PHOX in the effect of all the femtomolar-act-
ing compounds we tested, it seems likely that
PHOX is a potential target for fMLP.
PD has been proposed to be a multi-
factorial disease resulting from a combination
of normal aging, genetic deﬁcits, and environ-
mental injuries (Snyder and Adler 2007). The
impact of systemic infection on the progres-
sion of neurodegenerative diseases has been
documented (Arai et al. 2006; Combrinck
et al. 2002; Panitch 1994), and several circu-
lating cytokines (interferon-γ and TNF-α)
(Perry et al. 2003; Qin et al. 2007) have been
proposed to be important mediators. In the
present study, we demonstrated that sub-
picomolar fMLP induces speciﬁc degeneration
to DA neurons and thus might serve as a
mediator between infectious diseases and
neurodegeneration. fMLP may constantly gain
entrance into the CNS through circumven-
tricular organs (Duvernoy et al. 2007) during
chronic peripheral infectious diseases when
there is persistent circulating fMLP. Although
the inﬁltrated fMLP in this condition might
Neurotoxicity of fMLP via microglial activation
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Figure 4. Role of microglial PHOX in subpicomolar fMLP-induced DA neurotoxicity in mesencephalic rat
primary N/G cultures. (A) DA neurotoxicity determined by the [3H]DA uptake assay in mesencephalic N/G
cultures 8 days after pretreatment with DPI (10–9 M) or apocynin (0.2 mM) for 30 min and treatment with
fMLP (10–13M); values are mean ± SD of at least three separate experiments in triplicate. (B) DA neurotoxi-
city determined by the [3H]DA uptake assay in mesencephalic N/G cultures from gp91PHOX+/+ and
gp91PHOX–/– mice treated with vehicle or fMLP (10–13 M) for 8 days; values are mean ± SD from three inde-
pendent experiments in triplicate. (C) Activation of microglia visualized by immunostaining of Iba-1 antigen
in mesencephalic N/G cultures from gp91PHOX+/+ and gp91PHOX–/– mice treated with vehicle, LPS (5 ng/mL),
or fMLP (10–13 M) for 24 hr. Images are representative of three independent experiments; bar = 50 µm.
*p < 0.05 compared with control cultures. **p < 0.05 compared with fMLP-alone-treated cultures.
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fMLPnot be as high as it is in the blood, or even
under detectable levels, it could still be a
potential threat to DA neurons because fMLP
is toxic to DA neurons at concentration as low
as 10–13 M. In addition, in a number of acute
cerebral pathologies, including stroke, trauma,
and meningitis, the blood–brain barrier per-
meability increases, allowing plasma proteins
to enter the brain parenchyma. In PD
patients, dysfunction of the blood–brain bar-
rier was also observed (Kortekaas et al. 2005).
Because the peripheral circulating fMLP is a
small molecular-weight tripeptide, it is likely
able to pass through the blood–brain barrier
during inflammation. fMLP-induced PMN
activation resulted in an increase in endothe-
lial cell permeability (Gautam et al. 1998).
This may also occur to the blood–brain barrier
during the process of inflammation, which
would further facilitate fMLP penetration.
Given all these possibilities for fMLP to enter
the CNS and the innate vulnerabilities of the
nigro-striatal dopaminergic system (Block
et al. 2007), the results of the present study
highlight the potential role of infectious agents
in neurodegenerative diseases and may aid in
the development of new therapies.
REFERENCES
Arai H, Furuya T, Mizuno Y, Mochizuki H. 2006. Inflammation
and infection in Parkinson’s disease. Histol Histopathol
21:673–678.
Babior BM. 1999. NADPH oxidase: an update. Blood
93(5):1464–1476.
Balazovich KJ, Suchard SJ, Remick DG, Boxer LA. 1996. Tumor
necrosis factor-alpha and FMLP receptors are functionally
linked during FMLP-stimulated activation of adherent
human neutrophils. Blood 88(2):690–696.
Beckman JS, Carson M, Smith CD, Koppenol WH. 1993. ALS,
SOD and peroxynitrite. Nature 364(6438):584.
Block ML, Li G, Qin L, Wu X, Pei Z, Wang T, et al. 2006. Potent
regulation of microglia-derived oxidative stress and
dopaminergic neuron survival: substance P vs. dynorphin.
FASEB J 20(2):251–258.
Block ML, Zecca L, Hong JS. 2007. Microglia-mediated neuro-
toxicity: uncovering the molecular mechanisms. Nat Rev
Neurosci 8(1):57–69.
Chen K, Iribarren P, Huang J, Zhang L, Gong W, Cho EH, et al.
2007. Induction of the formyl peptide receptor 2 in microglia
by IFN-gamma and synergy with CD40 ligand. J Immunol
178(3):1759–1766.
Combrinck MI, Perry VH, Cunningham C. 2002. Peripheral infec-
tion evokes exaggerated sickness behaviour in pre-clinical
murine prion disease. Neuroscience 112(1):7–11.
Cui YH, Le Y, Gong W, Proost P, Van Damme J, Murphy WJ, et al.
2002a. Bacterial lipopolysaccharide selectively up-regulates
the function of the chemotactic peptide receptor formyl
peptide receptor 2 in murine microglial cells. J Immunol
168(1):434–442.
Cui YH, Le Y, Zhang X, Gong W, Abe K, Sun R, et al. 2002b. Up-
regulation of FPR2, a chemotactic receptor for amyloid beta
1-42 (A beta 42), in murine microglial cells by TNF alpha.
Neurobiol Dis 10(3):366–377.
Dewald B, Baggiolini M. 1985. Activation of NADPH oxidase in
human neutrophils. Synergism between fMLP and the
neutrophil products PAF and LTB4. Biochem Biophys Res
Commun 128(1):297–304.
Duvernoy HM, Risold PY. 2007. The circumventricular organs:
an atlas of comparative anatomy and vascularization.
Brain Res Rev 56(1):119–147.
Elbim C, Chollet-Martin S, Bailly S, Hakim J, Gougerot-
Pocidalo MA. 1993. Priming of polymorphonuclear neutro-
phils by tumor necrosis factor alpha in whole blood:
identiﬁcation of two polymorphonuclear neutrophil subpopu-
lations in response to formyl-peptides. Blood 82(2):633–640.
Fu H, Bylund J, Karlsson A, Pellme S, Dahlgren C. 2004. The
mechanism for activation of the neutrophil NADPH-oxidase
by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-
Val-Met differs from that for interleukin-8. Immunology
112(2):201–210.
Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. 2002.
Microglial activation-mediated delayed and progressive
degeneration of rat nigral dopaminergic neurons: relevance
to Parkinson’s disease. J Neurochem 81(6):1285–1297.
Gautam N, Hedqvist P, Lindbom L. 1998. Kinetics of leukocyte-
induced changes in endothelial barrier function. Br J
Pharmacol 125(5):1109–1114.
Hartt JK, Barish G, Murphy PM, Gao JL. 1999. N-Formylpeptides
induce two distinct concentration optima for mouse
neutrophil chemotaxis by differential interaction with two
N-formylpeptide receptor (FPR) subtypes. Molecular char-
acterization of FPR2, a second mouse neutrophil FPR. J Exp
Med 190(5):741–747.
Hirsch EC, Hunot S, Damier P, Faucheux B. 1998. Glial cells and
inflammation in Parkinson’s disease: a role in neuro-
degeneration? Ann Neurol 44(3 suppl 1):S115–120.
Jenner P. 2003. Oxidative stress in Parkinson’s disease. Ann
Neurol 53(suppl 3):S26–36.
Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W,
Bart J, Willemsen AT, et al. 2005. Blood-brain barrier dys-
function in parkinsonian midbrain in vivo. Ann Neurol
57(2):176–179.
Le Y, Li B, Gong W, Shen W, Hu J, Dunlop NM, et al. 2000. Novel
pathophysiological role of classical chemotactic peptide
receptors and their communications with chemokine
receptors. Immunol Rev 177:185–194.
Leenders KL, Oertel WH. 2001. Parkinson’s disease: clinical
signs and symptoms, neural mechanisms, positron emission
tomography, and therapeutic interventions. Neural Plast
8(1-2):99–110.
Liu B, Du L, Hong JS. 2000. Naloxone protects rat dopaminergic
neurons against inflammatory damage through inhibition
of microglia activation and superoxide generation.
J Pharmacol Exp Ther 293(2):607–617.
Liu B, Gao HM, Wang JY, Jeohn GH, Cooper CL, Hong JS. 2002.
Role of nitric oxide in inflammation-mediated neuro-
degeneration. Ann N Y Acad Sci 962:318–331.
Liu B, Qin L, Yang SN, Wilson BC, Liu Y, Hong JS. 2001.
Femtomolar concentrations of dynorphins protect rat mes-
encephalic dopaminergic neurons against inflammatory
damage. J Pharmacol Exp Ther 298(3):1133–1141.
Lorton D, Schaller J, Lala A, De Nardin E. 2000. Chemotactic-
like receptors and Abeta peptide induced responses in
Alzheimer’s disease. Neurobiol Aging 21(3):463–473.
McGeer PL, Itagaki S, Boyes BE, McGeer EG. 1988. Reactive
microglia are positive for HLA-DR in the substantia nigra
of Parkinson’s and Alzheimer’s disease brains. Neurology
38(8):1285–1291.
Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M,
Nagatsu T. 1996. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and
transforming growth factor-alpha levels are elevated in
ventricular cerebrospinal fluid in juvenile parkinsonism
and Parkinson’s disease. Neurosci Lett 211(1):13–16.
Nagatsu T, Sawada M. 2007. Biochemistry of postmortem
brains in Parkinson’s disease: historical overview and
future prospects. J Neural Transm Suppl 72:113–120.
Ofﬁce of Laboratory Animal Welfare. 2002. Public Health Services
Policy on Humane Care and Use of Laboratory Animals.
Bethesda, MD:Ofﬁce of Laboratory Animal Welfare.
Panaro MA, Mitolo V. 1999. Cellular responses to FMLP chal-
lenging: a mini-review. Immunopharmacol Immunotoxicol
21(3):397–419.
Panitch HS. 1994. Influence of infection on exacerbations of
multiple sclerosis. Ann Neurol 36(suppl):S25–28.
Paravicini TM, Drummond GR, Sobey CG. 2004. Reactive oxy-
gen species in the cerebral circulation: physiological roles
and therapeutic implications for hypertension and stroke.
Drugs 64(19):2143–2157.
Perry VH, Newman TA, Cunningham C. 2003. The impact of sys-
temic infection on the progression of neurodegenerative
disease. Nat Rev Neurosci 4(2):103–112.
Qin L, Block ML, Liu Y, Bienstock RJ, Pei Z, Zhang W, et al.
2005. Microglial NADPH oxidase is a novel target for fem-
tomolar neuroprotection against oxidative stress. FASEB J
19(6):550–557.
Qin L, Liu Y, Cooper C, Liu B, Wilson B, Hong JS. 2002. Microglia
enhance beta-amyloid peptide-induced toxicity in cortical
and mesencephalic neurons by producing reactive oxygen
species. J Neurochem 83(4):973–983.
Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, et al. 2007.
Systemic LPS causes chronic neuroinﬂammation and pro-
gressive neurodegeneration. Glia 55(5):453–462.
Roepstorff K, Rasmussen I, Sawada M, Cudre-Maroux C,
Salmon P, Bokoch G, et al. 2007. Stimulus dependent regu-
lation of the phagocyte NADPH oxidase by a VAV1, rac1,
and PAK1 signaling axis. J Biol Chem 283(12):7983–7993.
Sakamoto K, Kuribayashi F, Nakamura M, Takeshige K. 2006.
Involvement of p38 MAP kinase in not only activation of
the phagocyte NADPH oxidase induced by formyl-
methionyl-leucyl-phenylalanine but also determination of
the extent of the activity. J Biochem 140(5):739–745.
Snyder CH, Adler CH. 2007. The patient with Parkinson’s disease:
part I-treating the motor symptoms; part II-treating the non-
motor symptoms. J Am Acad Nurse Pract 19(4):179–197.
Videm V, Strand E. 2004. Changes in neutrophil surface-receptor
expression after stimulation with FMLP, endotoxin, inter-
leukin-8 and activated complement compared to degranula-
tion. Scand J Immunol 59(1):25–33.
Yang S, Yang J, Yang Z, Chen P, Fraser A, Zhang W, et al. 2006.
Pituitary adenylate cyclase-activating polypeptide (PACAP)
38 and PACAP4-6 are neuroprotective through inhibition of
NADPH oxidase: potent regulators of microglia-mediated
oxidative stress. J Pharmacol Exp Ther 319(2):595–603.
Yao J, Harvath L, Gilbert DL, Colton CA. 1990. Chemotaxis by a
CNS macrophage, the microglia. J Neurosci Res 27(1):36–42.
Yasuda Y, Shinagawa R, Yamada M, Mori T, Tateishi N,
Fujita S. 2007. Long-lasting reactive changes observed in
microglia in the striatal and substantia nigral of mice after
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res
1138:196–202.
Gao et al.
598 VOLUME 116 | NUMBER 5 | May 2008 • Environmental Health Perspectives